| INTRODUC TI ON
Compared to clinical and radiographic examinations, ultrasound (US) examinations provide a straightforward and more accurate detection of both inflammation and damage at the joint level. In this regard, Nakagomi et al reported that US-verified synovitis in clinically non-swollen joints may be alternatively used to increase the number of involved joints to fulfill the classification criteria. 8 We reported that US-detected synovitis, especially with moderate or severe power Doppler (PD) signals, is useful to predict the progression from undifferentiated arthritis (UA) not fulfilling the classification criteria for RA. 9 We also proposed a classification system named the "Nagasaki score" which uses the objective measures of magnetic resonance imaging (MRI) findings and seropositivity for predicting the progression from UA to RA. 10, 11 In those studies, the patients who were positive for at least 2 of the 3 Nagasaki score measures (ie (1) MRI-proven symmetric synovitis; (2) MRI-proven bone edema and/or bone erosion; and (3) anti-cyclic citrullinated peptide antibodies (ACPA) and/ or immunoglobulin M-rheumatoid factor (RF)) progressed to RA at 1 year with a 79.7% positive predictive value (PPV), a 63.0% negative predictive value, 75.9% specificity, 68.0% sensitivity, and 71.3%
accuracy.
We conducted the present study to identify an objective and convenient classification strategy for early-stage RA based on the use of US instead of MRI. We also confirmed the reproducibility of the results obtained at another center. In addition, we evaluated the differences between seropositive and seronegative RA patients confirmed by US.
| MATERIAL S AND ME THODS

| Patients
We consecutively recruited 216 patients at Nagasaki University Hospital (Hospital 1) and 223 patients at Isahaya General Hospital (Hospital 2) who were suspected as having RA and who were examined by US during the period from August 2014 to May 2016.
The duration from the appearance of the patients' symptoms to their entry into the study was ≤6 months. We excluded patients who had experience with disease-modifying antirheumatic drugs (DMARDs) or glucocorticoids. The follow-up periods were ≥3 months. This study was a retrospective observational investigation using anonymized information. The patients gave their informed consent to be subjected to the protocol, which was approved by the Institutional Review Board (reference no. 10062546) of Nagasaki University Hospital. The patients were different from the population in our previous study. 
| Clinical diagnosis
A clinical diagnosis of RA was comprehensively made by Japan Index. In this study, if a JCR-certified rheumatologist had introduced a DMARD within the first 3 months based on the above-described examination, the patient was diagnosed as having RA.
| US assessment
The US examination of each patient was performed by 1 of 3 JCRcertified sonographers (SK, KF or AN). A systematic multiplanar grayscale (GS) and PD examination of each patient's joints and tendons was performed using an Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) or Ascendus system (Hitachi Medical, Tokyo, Japan) at Hospital 1, and a Logiq S8 system (GE Healthcare, Buckinghamshire, UK) at Hospital 2 and high-frequency (12-18 MHz) linear transducers.
PD was used depending on which Doppler modality was the most sensitive on the individual machines. The Doppler setting was adjusted at each hospital according to published recommendations; the range of pulse repetition frequency was 500-800 Hz and the range of velocity was 3.1 cm/s, with a low wall filter. 12 There was no change in the US settings during the study, and no upgrading of software.
Articular synovitis was assessed by US at 22 joints: bilateral wrist joints, 1st-5th metacarpophalangeal (MCP) joints, the interphalangeal joints, and the 2nd-5th proximal interphalangeal (PIP) joints.
Each joint was scored for GS as well as PD on a scale from 0 to 3. For the dichotomization of US-verified synovitis, we used the definition of GS synovial hypertrophy with the PD signal (ie GS grade ≥1 and PD grade ≥1). The sum of the GS scores or the PD scores was considered the total GS score or total PD score, respectively.
We also assessed the novel Outcome Measures in Rheumatology (OMERACT)-EULAR combined power Doppler ultrasound score (ie the cPD score) and the Global OMERACT-EULAR Synovitis Score (GLOESS)0.1 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The cPD score was combined with synovial hypertrophy shown by GS and PD. [13] [14] [15] The GLOESS was calculated from the sum of cPD scores for the bilateral 2nd-5th MCP joints. [13] [14] [15] The presence or absence of bone erosion was also noted. Erosion was defined as a cortical break seen in 2 perpendicular planes.
Tenosynovitis was investigated in the digital flexor tendons of the 1st-5th fingers, and the carpal extensor tendon (components [1] [2] [3] [4] [5] [6] and was defined as abnormal hypoechoic or anechoic material inside the tendon sheath, with PD signals in 2 perpendicular planes. 16 Peritendinitis of the digital extensor tendon was investigated by obtaining a dorsal scan of the MCP joints only at Hospital 1, and it was defined as the presence of hypoechoic swelling of the soft tissue surrounding a tendon with PD signals in 2 perpendicular planes. 17 At Hospital 1, the sonographers mutually confirmed the findings.
We evaluated the inter-observer agreement for the 3 readers by determining the kappa coefficient via the reading of randomly selected US-captured images of 4 patients from our database. The kappa coefficient of inter-reader reliability was 0.72-0.76 for the GS scores, 0.84-0.85 for the PD scores, 1.00 for tenosynovitis, and 0.92 for peritendinitis.
| Statistical analyses
Statistical analyses were performed using JMP Pro statistical soft- Regarding articular synovitis, the frequencies of GS grades ≥1, ≥2 and 3 synovial hypertrophy and those of PD grades ≥1, ≥2 and 3 vascularity at any joint were significantly higher in the RA patients compared to the non-RA patients (P < 0.0001), except for those of GS and PD grade 3 at Hospital 2. The median of the total GS and PD score was significantly higher in the RA patients compared to the non-RA patients (P < 0.0001). The cut-off value of the total PD score distinguishing RA patients was 2 at both hospitals: the area under the curve (AUC) was 0.91 at Hospital 1 and 0.88 at Hospital 2.
On the other hand, the cut-off value of total GS score distinguishing RA patients was 3 (AUC 0.84) at Hospital 1, and 2 (AUC 0.84) at Hospital 2. In addition, the frequencies of cPD grades ≥1, ≥2 and 3 and the medians of the total cPD score and the GLOESS were significantly higher in the RA patients compared to the non-RA patients (P < 0.0001). The cut-off values of total cPD score and GLOESS distinguishing RA patients were 3 (AUC 0.85) and 2 (AUC 0.75), respectively.
The frequencies of PD-positive tenosynovitis of a carpal extensor tendon and digital flexor tendon at any tendon were significantly higher in the RA patients (P < 0.0001) at both hospitals. Only 3 RA patients had PD-positive tenosynovitis without PD-positive articular synovitis. The frequencies of PD-positive peritendinitis of a digital extensor tendon at any tendon were also significantly higher in the RA patients (P < 0.0001) at Hospital 1 (not listed at Hospital 2).
The presence of bone erosion was not frequent (15.7% at Hospital 1 and 6.8% at Hospital 2), but it was significantly higher in the RA patients compared to the non-RA patients (P < 0.0001 at Hospital 1 and P = 0.0008 at Hospital 2).
| Diagnostic performance of 2010 ACR/EULAR criteria, serologic and US findings
Flow charts of the 2010 ACR/EULAR criteria are given in Figure S1 . Regarding US-verified articular synovitis, increasing the cut-off thresholds of the grade for GS, PD, and cPD have been shown to increase the specificity for RA but at the expense of decreased sensitivity ( Table 2 ). The presence of PD grade ≥2 at any joint had the best-balanced diagnostic performance at Hospitals 1 and 2.
Interestingly, the diagnostic performance of total PD score ≥2
was as high as the presence of PD grade ≥2 at any joint. The value of cPD grade was somewhat low compared to the PD grade. The values of GS, PD, and cPD contributing to the diagnostic performance for identifying RA in the patients with no clinical synovitis and in the patients whose cases did not fulfill the 2010 ACR/EULAR criteria are summarized in Table 3 . The similar efficacy of US indices for the diagnosis of RA even in the patients with no clinical synovitis and in those who did not meet the 2010 ACR/EULAR criteria is shown by the data in Table 3 .
| Diagnostic performance of combinations of US and serologic findings
The diagnostic performance of combinations of US and serologic findings is addressed in Compared with the PD grade, the use of the cPD grade with serologic findings was similarly effective, but the cPD grade requirement was 1 grade higher compared to the PD grade ( Table 4 ).
The diagnostic odds ratios of the US findings and the combinations of US and serologic findings at both hospitals are shown in Table S1 .
| Comparison of disease activity between seropositive and seronegative RA patients
The tender and swollen joint counts were not significantly different between the seropositive and seronegative RA patients (Table 5 ).
However, both of the acute-phase reactants, the clinical disease activity, and the US synovitis scores were significantly higher in the seronegative RA patients compared to the seropositive RA patients ( Figure 1 , Table 5 ).
The cut-off values of the total GS score and the total PD score for distinguishing the seropositive RA patients (n = 100) from the non-RA patients (n = 310) were 2 (AUC, sensitivity, specificity; 0. 
| D ISCUSS I ON
The On the other hand, among the patients who fulfilled the 2010 ACR/EULAR criteria, 24.8% had no US-verified synovitis and 28.2%
were diagnosed as non-RA. Therefore, in patients who are diagnosed as having RA based on the 2010 ACR/EULAR criteria, a reconfirmation of the presence of active synovitis using US is recommended. The data are median (interquartile range, Q 1-4 -Q 3/4 ) or as number (percentage). Within-group comparisons were assessed with Mann-Whitney U test and the χ 2 test (Fisher's exact probability test when appropriate).
Non-RA patients in Hospital 1 were UA (n = 39), osteoarthritis (n = 34), polymyalgia rheumatica (PMR, n = 12), Sjögren syndrome (SS, n = 11), reactive arthritis (n = 10), remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome (n = 5), spondyloarthritis (SpA, n = 5), fibromyalgia syndrome (FMS, n = 5), tendonitis (n = 5), undifferentiated connective tissue disease (n = 4), polymyositis/dermatomyositis (PM/DM, n = 3), systemic sclerosis (SSc, n = 3), systemic lupus erythematosus (SLE, n = 2), mixed connective tissue disease (MCTD, n = 2), palindromic rheumatism (n = 1), pseudogout (n = 1), drug-induced arthritis (n = 1), ganglion cyst (n = 1) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV, n = 1). Non-RA patients in hospital 2 were UA (n = 50), undifferentiated SpA (n = 44), osteoarthritis (n = 17), PMR (n = 10), palindromic rheumatism (n = 7), FMS (n = 6), RS3PE syndrome (n = 4), carpal tunnel syndrome (n = 4), SLE (n = 3), SS (n = 3), tendonitis (n = 3), pseudogout (n = 2), psoriatic arthritis (n = 2), AAV (n = 2), sternoclavicular arthritis (n = 2), infectious arthritis (n = 1), SSc (n = 1), DM (n = 1), MCTD (n = 1), and ankylosing spondylitis (n = 1). ACPA, anti-cyclic citrullinated peptide antibody; ACR, American College of Rheumatology; cPD, composite power Doppler; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; GLOESS, Global OMERACT-EULAR Synovitis Score; GS, grayscale; PD, power Doppler; NS, not significant; NT, not tested; RA, rheumatoid arthritis; RF, rheumatoid factor. a Presence of at least 1 joint or tendon.
TA B L E 1 (Continued)
We reported the presence of PD grade ≥2 at any joint as a "wellbalanced contributing factor" for the diagnosis of RA, It is well known that MRI-verified bone edema is a strong predictor of the further development of RA and radiographic progression. 2, 10 In an earlier investigation, the prevalence of MRI-verified bone edema was increased in the joints of patients with articular synovitis of PD grade ≥2, whereas a lesser degree of MRI-verified bone edema was observed in the joints of patients with articular synovitis of PD grade 1, especially in wrist joints. 19 Therefore, instead of PD grade ≥2 at any joints, we evaluated and identified the cut-off TA B L E 2 Diagnostic performance of RA classification criteria, and serologic and ultrasound findings value of the total PD score for distinguishing RA patients; its value was 2 at both hospitals in this study. Although an US examination is also skill-dependent, the reliability of PD assessments is known to be high. 20 We thus consider a PD assessment acceptable as an objective diagnostic indicator.
The EULAR-OMERACT attempted to establish a single US scoring system based on the combined PD and GS (cPD score), especially for multicenter clinical trials. [13] [14] [15] For the first time, the present study verified the cPD score for the application of the early diagnosis of RA. Although the diagnostic accuracy of the cPD is slightly low 
TA B L E 5
Comparison of characteristics between seropositive and seronegative RA patients
Comparison of disease activity between the seropositive (n = 100) and seronegative (n = 29) RA patients. Within-group comparisons were made using Mann-Whitney U test. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GS, gray-scale; PD, power Doppler; RA, rheumatoid arthritis compared to PD, the cPD may be applicable in the arthritis diagnostic procedure. Regarding specificity, compared to PD, the use of the cPD requires a more intense grade to achieve an equivalent value.
This could be explained by the fact that the synovial vascularity (ie as shown by PD) more accurately reflects synovial tissue pathology than synovial hypertrophy (as shown by GS) 21, 22 and the cPD contains both PD and GS components.
A prospective cohort study indicated that a positive and especially a high titer of autoantibodies strongly predicted the development of clinical synovitis in patients with arthralgia. 23 We expected to achieve an early and accurate diagnosis of RA by com- (Table S2 ). The performance of ACPA for diagnosing RA is more specific than that of RF, 9,24,25 but our present findings suggest the utility of the use of RF and/or ACPA for the early diagnosis of RA, probably due to the combinational use of the PD signal provided by US.
We assessed abnormalities of tendons in this study.
Tenosynovitis is frequent in RA patients and is often one of the first signs of early-stage RA. [26] [27] [28] In the present study, approximately 1/3 of the RA patients had US-verified tenosynovitis.
However, a few of the patients with RA had only a tendon abnor- In a recent study, seronegative RA patients had more inflammatory activity, assessed by both clinical and US indices, compared to seropositive RA patients among DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria. 29 The disease duration of the our present patients is much shorter than that in the previous study, We compared the cut-off values of the total PD, GS and cPD scores, and GLOESS from 3 viewpoints: (1) distinguishing RA; (2) distinguishing seropositive RA; and (3) distinguishing seronegative RA from non-RA patients. Our analyses revealed that the total PD score of 2 is the only constant index distinguishing RA, seropositive RA, and seronegative RA from non-RA patients, whereas the cut-off values of the other 3 indices were different in each patient subgroup.
It is also interesting to note that the diagnostic performance of the total PD score ≥2 was higher in the seronegative RA patients compared to the seropositive RA patients (AUC 0.96 in seronegative RA vs 0.88 in seropositive RA). Taken together, our findings indicate that the PD score may be more useful than the GS score and the cPD score, and that the benefit of adding the measurement of the PD score to routine assessments seems to be greatest in seronegative patients.
Several limitations of this study should be acknowledged. First, this was a retrospective observational study in clinical practice.
Since the study was not double-blinded, a clinical diagnosis was comprehensively made by physicians based on all information including US and serologic findings. A second limitation is a selection bias. At Hospital 2, US was not performed for patients whose diagnosis was clinically obvious. Therefore, the frequency of patients finally diagnosed as having RA, the frequency of patients whose cases fulfilled the 2010 ACR/EULAR criteria, and the frequency of patients who had GS grade 3 or PD grade 3 synovitis were low in Hospital 2 compared to Hospital 1. Nevertheless, US demonstrated a good diagnostic performance in both hospitals' cohorts. Third, US was performed only on wrist and finger joints in this study, and thus a small number of patients who have no synovitis of wrist or finger joints may have been overlooked. Our proposal can be substituted in other joints, but further research is necessary regarding this point.
In conclusion, we are able to accurately identify patients who need treatment at the earliest stage of RA by using the combination of US and serologic findings, which are objective indicators. The combination criteria similarly demonstrated good diagnostic performance in different hospitals.
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